Clinical trial · no report yet · Phase 3
CheckMate 9DX
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
- NCT03383458 ↗
- Active not recruiting
- Bristol-Myers Squibb
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Hepatocellular Carcinoma; Liver Cancer
- Interventions
- Nivolumab; Placebo
- Arms
- Arm A · Experimental
- Arm B · Placebo comparator
- Enrollment
- 545
- Primary outcomes
- Recurrence-free Survival (RFS)
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Apr 18, 2018
- Primary completion
- May 27, 2026
- Results posted
- No
- Registry record
- NCT03383458 · updated Jul 31, 2026